SCHEMBL24917279

SCHEMBL24917279

CC(C)(C)OC(=O)N[C@](C)(Cc1ccc(F)cc1)C(=O)Nc1nncn2c([C@]3(C#N)O[C@H](CO)[C@H]4OC(C)(C)O[C@H]43)ccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24917278 0.93 — —
SCHEMBL24917277 0.90 — —
SCHEMBL24917170 0.86 TMPRSS2 (0.42) —
SCHEMBL24917169 0.77 TMPRSS2 (0.34) —
SCHEMBL25909472 0.72 CTSS (0.42) —
SCHEMBL24917667 0.71 PI4KA (0.33) —
SCHEMBL24304929 0.71 TMPRSS2 (0.49) —
SCHEMBL24916966 0.71 CYP3A4 (0.36) —
SCHEMBL24917300 0.68 TMPRSS2 (0.32) —
SCHEMBL24917698 0.67 TMPRSS2 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230024722-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-01-26 — — US disclosed
Send feedback